Stakeholder Opinions: Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression
Report
Market StudyStakeholder Opinions: Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.
In 2005, around 30,000 renal transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, daily immunosuppression therapy is a necessity for the lifetime of the graft with a base maintenance drug (cyclosporine, tacrolimus, sirolimus) combined with adjunctive therapies (azathioprine, mycophenolate mofetil, steroids).
Scope
Historical and recent trends in immunosuppressive therapy including current clinical practice and clinical advantages and side effects of treatments
Organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance populations to 2015
Primary diagnosis, graft survival rates, reasons for late graft failure and risk factors associated with acute rejection
Future market outlook including calcineurin inhibitor avoidance/withdrawal strategies
Highlights
30,000 renal transplants were performed in 2005, increasing to 43,000 by 2015 (CAGR, 2005-15, 4%), although the “organ gap†may widen further as increasing morbidity, such as diabetes mellitus, drives demand.
The number of patients with functioning kidney transplants will double to 428,000 by 2015, creating a large group of patients with unique and complex long-term medical care needs directly attributable to adverse effects of immunosuppressive drugs, including nephrotoxicity, diabetes, hypertension, hyperlipidemia and vulnerability to infection.
Although prevention of acute rejection remains a primary treatment goal, agents that do not impair long-term renal function are required. While results from sirolimus based calcineurin-inhibitor withdrawal regimens are inconclusive more promising results are emerging from use in the calcineurin-inhibitor avoidance or switching setting.
Reasons to Purchase
Identify changing trends in immunosuppressive protocols
Understand the most common treatment protocols in renal transplantation by patient type
Quantify the future market size based on the number of transplants and renal maintenance populations
Market StudyStakeholder Opinions: Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.